![]() | |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C24H20F3N3O |
Molar mass | 423.439 g·mol−1 |
3D model (JSmol) | |
| |
|
RO-4491533 is a drug developed by Hoffmann-La Roche which acts as a potent and selective negative allosteric modulator for group II of the metabotropic glutamate receptors (mGluR2/3), being equipotent at mGluR2 and mGluR3 but without activity at other mGluR subtypes. In animal studies, RO-4491533 produced antidepressant effects and reversed the effects of the mGluR2/3 agonist LY-379,268 with similar efficacy but slightly lower potency than the mGluR2/3 antagonist LY-341,495.[1] A number of related compounds are known, with similar effects in vitro and a fairly well characterized structure-activity relationship.[2]
| |
---|---|
1,4-Benzodiazepines |
|
1,5-Benzodiazepines |
|
2,3-Benzodiazepines* |
|
Triazolobenzodiazepines |
|
Imidazobenzodiazepines |
|
Oxazolobenzodiazepines |
|
Thienodiazepines |
|
Thienotriazolodiazepines |
|
Thienobenzodiazepines* |
|
Pyridodiazepines |
|
Pyridotriazolodiazepines |
|
Pyrazolodiazepines |
|
Pyrrolodiazepines |
|
Tetrahydroisoquinobenzodiazepines |
|
Pyrrolobenzodiazepines* |
|
Benzodiazepine prodrugs |
|
* atypical activity profile (not GABAA receptor ligands) |
![]() | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |